Anticonvulsant properties of the novel nootropic agent nefiracetam in seizure models of mice and rats

Epilepsia

Volumn 46, Issue 6, 2005, Pages 811-818

  Kitano, Yutaka ^a,c   Komiyama, Chika ^a   Makino, Mitsuhiro ^a   Takasuna, Kiyoshi ^a   Takazawa, Akira ^b   Sakurada, Shinobu ^c  

^a DAIICHI SANKYO CO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antiepileptic; Levetiracetam; Nefiracetam; Nootropic; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; BICUCULLINE; CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; N METHYL DEXTRO ASPARTIC ACID; NEFIRACETAM; NOOTROPIC AGENT; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; PIRACETAM; STRYCHNINE; VALPROIC ACID; ZONISAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ELECTRIC SHOCK; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE;

ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROSHOCK; MALE; MICE; NOOTROPIC AGENTS; PENTYLENETETRAZOLE; PIRACETAM; PYRROLIDINONES; RATS; RATS, WISTAR; SEIZURES;

EID: 20544473013     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2005.66504.x     Document Type: Article

References (58)

1. Giurgea CE. The nootropic concept and its prospective implications. Drug Dev Res 1982;2:441-6.
2. Gouliaev AH, Senning A. Piracetam and other structurally related nootropics. Brain Res Rev 1994;19:180-222.
3. Sarter M. Taking stock of cognition enhancers. Trends Pharmacol Sci 1991;12:456-61.
4. Hiramatsu M, Shiotani T, Kameyama T, et al. Effects of nefiracetam on amnesia animal models with neuronal dysfunctions. Behav Brain Res 1997;83:107-15.
5. Nabeshima T, Noda Y, Tohyama K, et al. Effects of DM-9384 in a model of amnesia based on animals with GABAergic neuronal dysfunctions. Eur J Pharmacol 1990;178:143-9.
6. A and muscarinic receptors induced by cyclohexamide. J Pharmacol Exp Ther 1991;257:271-5.
7. Sakurai T, Ojima H, Yamasaki T, et al. Effects of N-(2,6-dimethylphenyl)- 2-(2-oxo-1-pyrrolidinyl)acetamide (DM-9384) on learning and memory in rats. Jpn J Pharmacol 1989;50:47-53.
8. Yoshii M, Watabe S. Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG10815 cells. Brain Res 1994;642:123-31.
9. Yoshii M, Watabe S, Sakurai T, et al. Cellular mechanisms underlying cognition-enhancing actions of nefiracetam (DM-9384). Behav Brain Res 1997;83:185-8.
10. Abe E. Reversal effect of DM-9384 on scopolamine-induced acetylcholine depletion in certain regions of the mouse brain. Psychopharmacology (Berl) 1991;105:310-6.
11. Abe E, Murai S, Saito H, et al. Effects of nefiracetam, a novel pyrrolidone derivative, on brain monoamine metabolisms in mice. J Neural Transm (Gen Sect) 1992;90:125-36.
12. Kawajiri S, Taniguchi K, Sakurai T, et al. Nefiracetam enhances acetylcholine outflow from the frontal cortex: in vivo microdialysis study in the rat. J Neural Transm (Gen Sect) 1994;98:15-22.
13. Sakurai T, Kato T, Mori K, et al. Nefiracetam elevates extracellular acetylcholine level in the frontal cortex of rats with cerebral cholinergic dysfunctions: an in vivo microdialysis study. Neurosci Lett 1998;246:69-72.
14. Watabe S, Yamaguchi H, Ashida S. DM-9384, a new cognition-enhancing agent, increases the turnover of components of GABAergic system in the rat cerebral cortex. Eur J Pharmacol 1993;238:303-9.
15. Watabe S, Taniguchi K, Kojima H. Improvement of impaired brain monoamine metabolism by the cognition-enhancing agent nefiracetam after microsphere-induced cerebral embolism in rats. Arzneimittelforschung 1994;44:195-8.
16. Schmidt J. Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomed Biochim Acta 1990;49:413-9.
17. Hawkins CA, Mellanby JH. Piracetam potentiates the antiepileptic action of carbamazepine in chronic experimental limbic epilepsy. Acta Neurol Scand 1986;74(suppl 109):117-21.
18. Mondadori C, Schmutz M. Synergistic effects of oxiracetam and piracetam in combination with antiepileptic drugs. Acta Neurol Scand 1986;74(suppl 109):113-6.
19. Shorvon S. Pyrrolidone derivatives. Lancet 2001;358:1885-92.
20. Uthman BM, Reichl A. Progressive myoclonic epilepsies. Curr Treat Options Neurol 2002;4:3-17.
21. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000;2:99-105.
22. Gower AJ, Noyer M, Verloes R, et al. 1059, a novel anticonvulsant drug: pharmacological profile in animals. Eur J Pharmacol 1992;222:193-203.
23. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998;353:191-206.
24. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993;232:147-58.
25. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51:31-71.
26. Kitano Y, Makino M, Usui C, et al. General pharmacological profile of the new cognition-enhancing agent nefiracetam. Arzneimittelforschung 1994;44:199-210.
27. Shiotani T, Nakamoto Y, Watabe S, et al. Anticonvulsant actions of nefiracetam on epileptic EL mice and their relation to peripheral-type benzodiazepine receptors. Brain Res 2000;859:255-61.
28. Hashizume K, Kunimoto M, Maeda T, et al. Antiepileptic effect of nefiracetam on kainic acid-induced limbic seizure in rats. Epilepsy Res 2000;39:221-8.
29. Tanaka T, Hashizume K, Sawamura A, et al. Basic science and epilepsy: experimental epilepsy surgery. Stereotact Funct Neurosurg 2001;77:239-44.
30. Fisher RS. Animal models of the epilepsies. Brain Res Rev 1989;14:245-78.
31. Kupferberg HJ. Antiepileptic drug development program: a cooperative effort of government and industry. Epilepsia 1989;30(suppl 1):S51-6.
32. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs?: a proposal based on experimental and clinical considerations. Epilepsy Res 1988;2:145-81.
33. Kitano Y, Komiyama C, Makino M, et al. Anticonvulsant properties of the novel nootropic agent nefiracetam (DM-9384) on seizure models of mice. Epilepsia 1999;40(suppl 2):125.
34. Löscher W, Frey HH. Evaluation of anticonvulsant drugs in gerbils with reflex epilepsy. Arzneimittelforschung 1984;34:1484-8.
35. Masuda Y, Karasawa T, Shiraishi Y, et al. 3-Sulfamoylmethyl-1,2- benzisoxazole, a new type of anticonvulsant drug: pharmacological profile. Arzneimittelforschung 1980;30:477-83.
36. Masuda Y, Shiraishi Y, Karasawa T, et al. Differential antagonisms of anticonvulsants to various components of maximal seizures induced by electroshock or pentylenetetrazol in mice. J Pharmacobiodyn 1980;3:526-31.
37. Bailleux V, Vallée L, Nuyts JP, et al. Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl)phthalimide and prototype antiepileptic drugs in mice and rats. Epilepsia 1995;36:559-65.
38. Kitano Y, Usui C, Takasuna K, et al. Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. J Pharmacol Toxicol Methods 1996;35:25-9.
39. LaRoche SM, Helmers SL. The new antiepileptic drugs: scientific review. JAMA 2004;291:605-14.
40. Aihara H, Li X, Fujiwara S, et al. The protective action of nefiracetam against electrophysiological and metabolic damage in the hippocampus after deprivation of glucose and oxygen. Brain Res 2001;922:158-62.
41. Fujita R, Takayama N, Ueda H. The cognition-enhancer nefiracetam is protective in BDNF-independent neuronal cell death under the serum-free condition. Neurochem Int 2002;40:139-43.
42. Ueda M, Fujita R, Koji T, et al. The cognition-enhancer nefiracetam inhibits both necrosis and apoptosis in retinal ischemic models in vitro and in vivo. J Pharmacol Exp Ther 2004;309:200-7.
43. Hasegawa M, Nakayama S, Kinoshita H, et al. Effects of the subacute administration of nefiracetam on abnormal behavior in aged rats. Behav Brain Res 1996;78:93-100.
44. Rashid MH, Ueda H. Nonopioid and neuropathy-specific analgesic action of the nootropic drug nefiracetam in mice. J Pharmacol Exp Ther 2003;303:226-31.
45. Fujikawa K, Akiyama Y, Takayama S. Drug dependence study of the new cognition-enhancing agent nefiracetam in rats. Arzneimittelforschung 1994;44:243-7.
46. Kajimura T, Satoh H, Rajasekaran D, et al. Oncogenicity studies of the cognition-enhancing agent nefiracetam in mice and rats. Arzneimittelforschung 1994;44:254-9.
47. Watanabe T, Matsuhashi K, Shimada M, et al. Reproductive toxicity studies of the new cognition-enhancing agent nefiracetam in rats and rabbits. Arzneimittelforschung 1994;44:239-42.
48. Sugawara T, Kato M, Furuhama K, et al. Single dose toxicity study of the new cognition-enhancing agent nefiracetam in mice, rats and dogs. Arzneimittelforschung 1994;44:211-3.
49. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-42.
50. Shorvon SD, Lowenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures: European Levetiracetam Study Group. Epilepsia 2000;41:1179-86.
51. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004;101:9861-6.
52. Madeja M, Margineanu DG, Gorji A, et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action? Neuropharmacology 2003;45:661-71.
53. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18.
54. Löscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998;342:1-13.
55. Trimble MR. Epilepsy and behaviour. Epilepsy Res 1991;10:71-9.
56. Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 2002;62:593-604.
57. Chaudhry HR, Najam N, de Mahieu C, et al. Clinical use of piracetam in epileptic patients. Curr Ther Res Clin Exp 1992;52:355-60.
58. Aldenkamp AP, Van Wieringen A, Alpherts WC, et al. Double-blind placebo-controlled, neuropsychological and neurophysiological investigations with oxiracetam (CGP 21690E) in memory-impaired patients with epilepsy. Neuropsychobiology 1990-1991;24:90-101.